FDA De Novo Classification Strategy

Preparing the De Novo Submission

Developing the De Novo application required more than compiling technical reports.

E&E Medicals structured the submission as a coherent scientific narrative demonstrating why the device represented a reasonable assurance of safety and effectiveness despite the absence of a predicate.

Each section of the submission built upon the previous one.

The device description established technological context.

Risk analyses demonstrated systematic hazard management.

Verification reports confirmed technical performance.

Clinical evidence supported intended use.

Software documentation established lifecycle control.

Cybersecurity documentation demonstrated protection of patient information and system integrity.

Quality system documentation reinforced organizational maturity.

Rather than overwhelming reviewers with excessive data, the submission emphasized scientific clarity, logical organization, and transparent decision-making.